Doxorubicin Hydrochloride Liposome is a Intravenous Injection, Suspension, Liposomal in the Human Prescription Drug category. It is labeled and distributed by Baxter Healthcare Corporation. The primary component is Doxorubicin Hydrochloride.
| Product ID | 0338-0086_1bbcb035-47b4-4a83-abf6-74c33725d3ec |
| NDC | 0338-0086 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Doxorubicin Hydrochloride Liposome |
| Generic Name | Doxorubicin Hydrochloride Liposome |
| Dosage Form | Injection, Suspension, Liposomal |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2019-08-15 |
| Marketing Category | NDA / NDA |
| Application Number | NDA050718 |
| Labeler Name | Baxter Healthcare Corporation |
| Substance Name | DOXORUBICIN HYDROCHLORIDE |
| Active Ingredient Strength | 2 mg/mL |
| Pharm Classes | Anthracycline Topoisomerase Inhibitor [EPC],Anthracyclines [CS],Topoisomerase Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |